glp-1 for ckd agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity SGLT2 vs GLP-1 for CKD:

For many people and product developers alike, the open question is less what to prioritize and more how to apply these principles in everyday eating and formulation

Excess weight, in and of itself, is not a disease. When it comes to her patients, she says, shes a stickler for a holistic approach to health, including eating a nutritious diet (not just eating less) and daily physical activity, as essential elements of the weight-loss process

If raw capacity were the only issue, the problem would be tractable

Data extraction was done by two independent reviewers and arbitrated by a third reviewer

Temporal differences between activation of LKB1 and inhibition of the incretin-induced Ca 2+ response were observed after treatments with metformin, suggesting that activation of LKB1 precedes downstream signals